Shire’s constipation drug prucalopride is moving closer to market – advisers to the FDA have just unanimously backed it as a treatment for chronic idiopathic constipation (CIC) in adults.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.